Ischemia reperfusion injury (IRI) is one of the major risk factors associated with primary graft dysfunction, the leading cause of early mortality in heart transplant recipients. Here, we show that the proton-gated acid-sensing ion channel 1a (ASIC1a) plays a key role during cardiac ischemia and demonstrate that ASIC1a is a promising new target to improve the tolerance of cardiac tissue to IRI.
Introduction
Heart transplantation remains the most effective treatment option for patients with heart failure (HF), a disease that affects over 26 million people worldwide (1, 2) . It is estimated that 1 in 5 people develop heart failure, with an annual healthcare cost of $108B (3, 4) . Despite the effectiveness of heart transplantation, 75% of potential donor hearts are discarded, many due to donor heart sensitivity to ischemic injury (2) . Even in successfully transplanted hearts, primary graft dysfunction is a major risk for patients in the first 30 days after transplantation, and it accounts for 66% of patient deaths, of which 48% are due to ischemia-reperfusion injury (IRI) (5) . Furthermore, the relative risk of one-year morbidity following transplantation is strongly correlated with organ ischemic time (2, 6) . Myocardial sensitivity to IRI therefore remains a primary point of vulnerability underlying the number of available donor hearts and patient outcomes.
Myocardial IRI is a complex pathophysiological process that underlies the cardiac injury sustained during donor organ procurement, storage, and transplantation. During ischemia, reduced oxygen availability causes a shift from fatty acid metabolism to anaerobic glycolysis (7, 8) . The resulting lactic acidosis causes the extracellular pH to fall to as low as 6.0-6.5 (9, 10) . Ongoing acidosis results in the activation of several transmembrane ion channels and receptors, including the sodium-hydrogen exchanger (NHE), glutamate-gated NMDA receptors, and the TRP family of ion channels, each of which are thought to contribute to calcium overload, metabolic dysfunction, and eventually cell death (11) (12) (13) .
Acid sensing ion channels (ASICs) are voltage-independent, proton-gated cation channels of the degenerin/epithelial sodium channel superfamily (14) . There are six ASIC isoforms derived from four genes (ACCN1-4), which assemble into homotrimeric or heterotrimeric channels. The pH sensitivity and kinetics of ASICs are determined by their subunit composition (15, 16) . ASICs are involved in extracellular acidification-induced calcium overload in neurons and cardiomyocytes (17) (18) (19) . ASIC1a, a splice variant of the ACCN1 gene, is the most pH-sensitive ASIC channel. Activation begins at pH ≤ 7, with half-maximal activation at pH 6.6 (20, 21) , and ASIC1a currents are potentiated by numerous metabolic events that occur during ischemia including membrane stretch and increased levels of extracellular lactate, pyruvate, and arachidonic acid (22, 23) . ASIC1a plays a critical role in mediating ischemia-induced neuronal death, and inhibition of ASIC1a through genetic ablation or pharmacological blockade is neuroprotective in rodent models of ischemic stroke (24) (25) (26) (27) . ASIC1a has not been studied in the context of cardiac ischemia and its role in the heart is largely unknown.
In this study, we used genetic and pharmacological approaches to demonstrate that ASIC1a is a critical mediator of the injury response to myocardial IRI. We show that venom-derived inhibitors 4 of ASIC1a provide robust cardioprotection across multiple species and model systems from the cellular to whole-organ level. We demonstrate a reproducible benefit in organ recovery using multiple models of donor heart preservation and provide compelling evidence that ASIC1a is an important target for cardioprotective drugs, with potential clinical application in whole heart transplantation.
Results
Genetic ablation of ASIC1a improves functional recovery following cardiac IRI. We assessed ASIC isoform expression in the adult mouse heart using transcriptomic data of sorted cardiac cell populations (28) . ASIC1 expression was highest in cardiomyocytes, while endothelial cells and fibroblasts expressed both ASIC1 and ASIC3. In all three cell types, ASIC4 and ASIC2 had low and undetectable expression, respectively ( Fig. 1A) . ASIC1 encodes two isoforms from the same genetic locus, ASIC1a
and ASIC1b, that are genetically conserved in bilaterians. As opposed to ASIC1b, which is primarily involved in nociception (29) , we focused on ASIC1a due to its known role in mediating ischemic injury in the brain (16).
To determine whether ASIC1a plays a functional role during cardiac ischemia, we assessed IRI tolerance of Langendorff-perfused isolated hearts from ASIC1a-specific knockout (KO) mice. To generate the ASIC1a KO mouse strain, we used CRISPR editing to target the ACCN1 locus. Specificity of the knockout was confirmed using qRT-PCR which showed that ASIC1a but not ASIC1b mRNA was reduced in brain tissue from knockout (KO) mice (Supplemental Fig. S1 ). Baseline function and heart rate in ASIC1a KO (ASIC1a -/-) isolated hearts were comparable to those measured in wild-type (WT) control hearts (ASIC1a +/+ ) ( Table 1) . To assess tolerance to IRI, hearts were subjected to 25 min of global normothermic zero-flow ischemia, followed by 45 min of aerobic reperfusion. WT and ASIC1a KO hearts showed similar initial responses to ischemia with comparable levels of ventricular contracture (Supplemental Fig. S2A ). During reperfusion, both groups demonstrated gradual recovery of contractile function over time, with markedly improved functional recovery in ASIC1a KO hearts ( Fig. 1B) . By the end of the reperfusion period, ASIC1a KO hearts had significantly improved systolic and diastolic function with higher left ventricular developed pressure (LVDP) (44 ± 5% of baseline) and lower end diastolic pressure (EDP) (38 ± 3 mmHg) compared to WT hearts (LVDP: 23 ± 7% of baseline; EDP: 50 ± 3 mmHg; Fig. 1 C and D) . ASIC1a KO hearts also had improved recovery of coronary flow (CF) rates by the end of reperfusion (KO: 97 ± 6%; WT: 78 ± 3%, percent baseline) ( Fig. 1E and Supplemental Fig. S2 B and C) . To assess cell death, lactate dehydrogenase (LDH) efflux was measured in perfusate samples collected during reperfusion. LDH efflux from ASIC1a KO hearts was significantly lower compared to WT hearts after 2 min of 5 reperfusion ( Fig. 1F) , with a similar trend at the end of reperfusion (Supplemental Fig. S2D ). Our data indicate that ASIC1a does not play a role in maintaining functional homeostasis, but it is a critical mediator of the organ response to myocardial IRI.
ASIC1a inhibitors protect mouse hearts against IRI. We sought to determine whether pharmacological inhibition of ASIC1a is similarly cardioprotective to genetic ablation of the channel.
Despite significant investment and preclinical testing, drug development pipelines have failed to identify effective small-molecule inhibitors of ASIC1a due to lack of specificity, potency, or functional efficacy (30) (31) (32) . We therefore took advantage of two venom-derived inhibitors of ASIC1a, both of which are highly selective for ASIC1a, with no effect on other ASIC isoforms (24, 26) . Hi1a is a 76residue double-knot peptide isolated from the venom of an Australian funnel-web spider ( Fig. 2A) ; it is the most potent and selective inhibitor of ASIC1a identified to date, with an IC50 on rat and human ASIC1a of ~500 pM (26) . PcTx1, a single-knot peptide from the venom of a tarantula, is also a potent and selective inhibitor of ASIC1a (IC50 ~1 nM) (24) . Although the two peptides are closely related (Hi1a is comprised of two PcTx1-like domains joined by a short linker; Fig. 2 B and C) , they have distinct inhibitory modes of action. Hi1a inhibits ASIC1a activation whereas PcTx1 promotes and stabilizes a desensitized state of the channel (26) . We also utilized an analogue of PcTx1 that contains mutations of two pharmacophore residues (R27A/V32A), which dramatically reduces its inhibitory effect on ASIC1a (24) .
To examine if these ASIC1a inhibitors are cardioprotective, we assessed tolerance to IRI in Langendorff-perfused isolated mouse hearts with and without peptide treatment. Consistent with genetic ablation of ASIC1a, Hi1a, PcTx1, and PcTx1-R27A/V32A had no effect on baseline contractile function during the first 10 min of peptide infusion prior to ischemia ( Fig. 2D) . Functional tolerance to IRI was greater in hearts exposed to Hi1a or PcTx1 (10 nM) compared to control hearts ( Fig. 2E) . At the end of reperfusion, Hi1a-and PcTx1-treated hearts, but not hearts treated with the functionally impaired PcTx1-R27A/V32A analogue, had markedly improved recovery of LVDP (Hi1a: 60 ± 4%, PcTx1: 49 ± 12%, PcTx1-R27A/V32A: 36 ± 6%) compared to vehicle controls (20 ± 4%) ( Fig. 2F) . Similarly, treatment with Hi1a and PcTx1, but not PcTx1-R27A/V32A, led to reduced EDP after 45 min reperfusion (Hi1a: 35 ± 4 mmHg; PcTx1: 33 ± 8 mmHg; PcTx1-R27A/V32A: 48 ± 3 mmHg) compared to vehicle controls (57 ± 2 mmHg) ( Fig. 2G) . No differences in final CF were observed between groups (Fig. 2H) , although hearts treated with PcTx1, but not Hi1a, displayed significant reactive hyperaemia during early reperfusion, as evidenced by increased CF during the first 5 min of reperfusion (Supplemental Fig. S3 A and B) . Taken together, our data show that ASIC1a inhibitors protect the heart from myocardial IRI and recapitulate the functional benefits of genetic 6 ablation of the channel.
Preconditioning with Hi1a improves functional recovery of isolated rodent hearts after prolonged
hypothermic ischemia. In order to evaluate the cardioprotective effect of ASIC1a inhibition in a model of donor heart preservation, we supplemented standard clinical heart preservation solution (Celsior (33)) with Hi1a during 8 h cold storage of isolated rat hearts. The hearts were stabilised for 10 min by retrograde (Langendorff) perfusion and then switched to working-mode in order to assess cardiac function in the presence of physiological afterload. Following assessment of baseline hemodynamic parameters, hearts were arrested by infusion of cold (2-3°C) Celsior solution with and without 10 nM Hi1a into the coronary circulation. After cardioplegic arrest, hearts were stored under hypothermic conditions for 8 h, followed by reperfusion and functional analysis ( Fig. 3A) . Hearts preserved with Hi1a supplementation had markedly improved recovery of aortic flow (AF) (50 ± 11%) and cardiac output (CO) (57 ± 8%) compared to Celsior-only controls (AF: 8 ± 5%; CO: 24 ± 5%) ( Fig. 3 B and C). These data demonstrate that Hi1a is highly cardioprotective against IRI in a clinically relevant model of donor heart preservation with prolonged cold storage.
Hi1a supplementation improves recovery in a post-conditioning model of donation after circulatory death.
To determine whether pharmacological inhibition of ASIC1a could recover hearts when delivered subsequent to a profound ischemic injury, we assessed the effect of Hi1a in a rodent model of donation after circulatory death (DCD). To mimic a clinical DCD withdrawal for heart transplantation in rodents, asphyxiation was induced via tracheal ligation, then the hearts were retrieved after a 10-min warm ischemic time (WIT) followed by 2-min stand-off period. Following ischemia, the hearts were flushed with Celsior with or without supplementation, followed by ex vivo reperfusion in Langendorff mode for 30 min and then working mode for an additional 30 min ( Fig.   4A ).
Hi1a (10 nM) was tested as a single supplement and in combination with two clinically used supplements, glyceryl trinitrate (GTN) and erythropoietin (EPO) (34) . As a positive control, we also evaluated zoniporide (Zon) combined with GTN and EPO, which we have previously shown activates ischemic postconditioning pathways through inhibition of NHE activity (35) . To assess the viability of hearts post-DCD withdrawal, functional parameters and cell death (LDH release) were measured throughout working-mode reperfusion. In Celsior-only controls, coronary effluent levels of LDH increased throughout the 30 min assessment period. Allografts supplemented with Hi1a, Hi1a + GTN/EPO, or GTN/EPO/Zon, however, had significantly reduced levels of LDH after 30 min, with 7 LDH release in both triple-supplemented groups comparable to a heart at baseline, prior to ischemic insult ( Fig. 4B) . Functional parameters of recovery including AF, CO, and pulse pressure (PP) were all significantly improved in supplemented groups compared to Celsior alone ( Fig. 4 C-E). AF, in particular, was significantly increased in hearts supplemented with Hi1a combined with GTN and EPO (32 ± 2 mL/min) compared to Hi1a as a single supplement (18 ± 3 mL/min), suggesting an additive effect of Hi1a with current clinically used cardioprotective agents ( Fig. 4C) .
To investigate the therapeutic benefit of Hi1a in the context of preventing cell death in DCD hearts, we performed western blots to examine the levels of phosphorylated RIP3 (pRIP3) in tissue lysates collected at the end of working-mode reperfusion. RIP3 is one of the key regulators of the necroptosis pathway that has been implicated in the response to IRI (36, 37) , and specifically to ASIC1a-mediated cell death during cerebral ischemia (38) . Treatment with Hi1a as a single or triple supplement led to reduced levels of pRIP3 following DCD withdrawal and reperfusion ( Fig. 4F ),
suggesting that Hi1a blockade of ASIC1a might inhibit necroptosis. Together with our finding that Hi1a improved donor organ viability after prolonged cold storage, the therapeutic efficacy of Hi1a in the DCD model demonstrates significant translational potential for ASIC1a-targeted therapies during clinical donor heart preservation. We next assessed whether natural variation in the genetic locus encoding ASIC1a (ACCN1) is associated with ischemic diseases using human population statistical genetics. While fewer than 10% of new molecular entities that pass through clinical trials are approved for therapeutic use, evidence of human genetic association between the gene target and traits sufficiently similar to the indication being treated increases the likelihood of approval to as high as 50% (40) . We utilized summary data from genome-wide association studies (GWAS) (41) and calculated the statistical significance (using fastBAT (42)) of genetic variants encompassing the ACCN1 locus with human cardiac and cerebral ischemic phenotypes. These data revealed a significant association between genetic variation in ACCN1 and major coronary heart disease and MI (P < 0.05) ( Table 2 ). We also found that genetic variation in ACCN1 associates with small-vessel ischemic stroke (p = 3.94 x 10 -3 ), but not other stroke subtypes ( Table 2) . Taken together, these data provide evidence that ACCN1 polymorphisms within the human population are associated with ischemic diseases of the heart and brain.
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ASIC1a inhibition prevents cell death in in vitro human models of IRI. To examine whether
pharmacological blockade of ASIC1a might provide therapeutic benefit in the context of human tissue, we used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Contractile cardiomyocytes were generated from stem cells using a standard monolayer-based differentiation protocol involving bi-phasic Wnt regulation ( Fig. 5A and Supplemental Fig. S5A ). Analysis of mRNA transcripts from single-cell RNA sequencing data over a time course of cardiac differentiation from pluripotency (43) revealed that ASIC1, ASIC3, and ASIC4 expression increased starting in day-5 cardiac progenitor populations and peaked in day-15 definitive cardiomyocytes. ASIC1 was the most highly expressed ASIC subtype, with expression levels comparable to other cardiac ion channels such as TRPV1 and NaV1.5 ( Fig. 5 B and C) .
Since ASIC1a mediates influx of calcium in addition to sodium (29), we performed calcium imaging after acute addition of the ASIC1a inhibitors Hi1a and PcTx1 to assess whether ASIC1a inhibition alters physiological electromechanical coupling in cardiomyocytes. Replated hiPSC-CMs were loaded with a fluorescent calcium dye and calcium transients were recorded before and after peptide addition. Neither Hi1a nor PcTx1 altered calcium amplitudes or spontaneous beating rate at any evaluated concentration ( Fig. 5D ).
To assess whether ASIC1a inhibition is cardioprotective in hiPSC-CMs, we evaluated cell To further confirm that ASIC1a plays a direct role in mediating cell death, we treated hiPSC-CMs overnight with 20 nM MitTx, a potent agonist of ASIC1a isolated from snake venom (44) . Consistent with ASIC1a mediating the injury response to cardiac ischemia, treatment of hiPSC-CMs with MitTx resulted in increased cell death at both pH 7.4 and pH 6.0 ( Fig. 5F) .
We next evaluated the cardioprotective effect of Hi1a and PcTx1 in an in vitro model of ischemia/acidosis with reperfusion. To mimic ischemia/acidosis in vitro, hiPSC-CMs were incubated overnight under combined hypoxic (0.5% O2) and acidic (pH 5.0) conditions with or without peptide.
After 18 h of incubation, the low-pH medium was replaced with medium at physiological pH 7.4 with or without peptide, and the cells were incubated for an additional hour under normoxic conditions. Significant cell death was observed in control hiPSC-CMs, but this was blocked by either 10 nM Hi1a or PcTx1 ( Fig. 5 G and H) . These data suggest that ASIC1a mediates cell death responses in human cardiomyocytes and that pharmacological inhibition of ASIC1a confers significant protection against ischemia-induced cell stress.
Discussion
In this study, we showed that ASIC1a exacerbates cardiomyocyte injury responses to ischemia, and that inhibition of ASIC1a during IRI affords significant cardioprotection. Although ASICs, and in particular ASIC1a, are generally associated with the central and peripheral nervous systems (45) , our expression analyses revealed that ASIC1 is present in both rodent and human cardiomyocytes, and is not differentially regulated at the transcriptional level as a result of cellular ischemia in vitro. Our evidence of ASIC1 expression in the heart is supported by recent studies that identified ASIC-like currents in hiPSC-CMs (46) and rat cardiomyocytes (17) . In neurons, there are several possible mechanisms by which ASIC1a activation leads to cell death including calcium overload (47), regulation of mitochondrial permeability transition (MPT) pores (48) , and the initiation of necroptosis through direct interaction with, and activation of, RIPK1 (38) . ASIC1a-induced cell death has not previously been described in cardiomyocytes, but there is evidence that ASIC1a, along with TRPV1, mediates calcium influx in response to extracellular acidosis (17) . Importantly, given the potential for ASIC1a to transport calcium, we showed that genetic ablation or pharmacological inhibition of ASIC1a does not alter normal electromechanical coupling in the heart in vitro or in vivo.
Our finding that ASIC1a blockade protects the heart from IRI-associated cardiac dysfunction is consistent with prior research demonstrating the importance of ASIC1a during cerebral ischemia (24) (25) (26) (27) , and it extends the potential therapeutic applications of ASIC1a-targeted therapies to cardiac applications, such as the preservation of donor hearts for transplantation. The majority of heart transplants are performed with hearts donated from brain dead (BD) donors, as hearts from the DCD pathway were historically considered unusable for transplantation due to the severe ischemic injury sustained during organ procurement (49) . Recent advances, however, have shown that successful transplantation of DCD hearts is possible with effective post-conditioning strategies, namely normothermic ex vivo perfusion and pharmacological post-conditioning. There are now active DCD transplant programmes in Australia and Europe, as well as a large multi-centre trial in the USA (34, 35, 50) . The viability of usable BD and DCD hearts, however, continues to be adversely affected by unavoidable injury to the heart that occurs during organ procurement and storage, as well as reperfusion injury in the recipient. The development of early interventions that reduce injury to the graft and reduce the risk of primary graft dysfunction in the recipient therefore remains a critical area of research and unmet need. 10 NHE inhibitors showed promise as an intervention for improving ischemic tolerance of DCD hearts (35, 51) , as well as in a number of other clinical indications of myocardial IRI including cardiac surgery (52) . However, in a Phase III clinical trial (the EXPEDITION Trial) of the NHE inhibitor cardiporide, cerebrovascular complications halted therapeutic development, despite promising clinical evidence that NHE inhibitors can be effective at reducing myocardial IRI (53) . Our direct comparison between Hi1a and current clinical preservation supplements as well as the NHE inhibitor, zoniporide, provide strong evidence for the clinical utility of ASIC1a inhibitors.
Given that drug targets with genetic evidence of disease association are twice as likely to succeed in clinical trials and lead to approved drug candidates (40) , our GWAS analysis of the association between genetic variation in the ACCN1 locus and ischemic disease points towards the translational potential of ASIC1a-targeted therapies. Such therapies have the potential to impact a broad scope of clinical applications since myocardial IRI is evident in many cardiovascular complications outside of heart transplantation, such as acute MI, out-of-hospital cardiac arrest (OHCA), and cardiopulmonary bypass surgery (2) . Despite intensive research into therapies aimed at mitigating myocardial IRI in the context of acute MI, none have translated into clinical practice (54) .
Furthermore, ASIC1a inhibitors might provide a potential major advantage for clinical use due to their ability to protect both the heart and the brain from IRI, which is particularly relevant for OHCA that results in cardiac and cerebral ischemia. In general, there is a strong association and co-morbidity between stroke and cardiac arrest, with 88% of patients suffering some form of cardiovascular complication within four weeks of an ischemic stroke (55) . Likewise, cardiac interventions such as transcatheter aortic valve implantation (TAVI) can cause cerebrovascular complications (56) . We previously used a rat model of ischemic stroke to show that a single dose of Hi1a (2 ng/kg i.c.v) massively reduced infarct size and improved neurological and motor performance even when administered up to 8 h after stroke onset (26) . No other drugs have been shown to provide significant protection beyond 4 h after stroke onset (57) .
Venom-derived molecules have proven to be a source of novel therapeutics, particularly in the cardiovascular field. Examples include the antihypertensive drug captopril (58) derived from the venom of a Brazilian viper, and eptifibatide and tirofiban, antiplatelet drugs that are used to treat acute coronary syndromes (59) . Disulfide-rich knottin peptides such as Hi1a are typically highly stable in biological fluids, and ziconitide, a knottin peptide derived from cone snail venom, is an FDA-approved analgesic (59) . For this reason, Hi1a is ideally suited for clinical use as an adjuvant to standard-of-care heart preservation solutions for heart transplant or in combination with mechanical procedures such as percutaneous coronary intervention for myocardial infarction.
In summary, we have shown that ASIC1a is a critical mediator of cell death during cardiac ischemia and that pharmacological inhibition of ASIC1a affords potent cardioprotection across rodent and human models of cardiac IRI. These findings suggest that ASIC1a inhibitors have the potential to significantly impact the public health burden of cardiovascular disease and result in improved outcomes for patients with cardiac ischemic injuries. 
Materials and Methods
Study
Donor heart preservation following circulatory death in rodents.
The rodent model of DCD (Fig. 4A) was developed by our laboratory to closely mimic the events that occur during withdrawal of life support (WLS) in the clinical scenario (66) . Male Wister rats (325-395 g) were anesthetized with an intraperitoneal injection of ketamine (80 mg/kg; Cenvet, Australia) and xylazine (10 mg/kg; Provet, Australia), with supplemental doses given as necessary until adequate anaesthesia was achieved. Noninvasive monitoring was established, consisting of measurement of pulse oximetry (Rad-5v, Masimo
Inc., Irvine, CA) and continuous electrocardiogram (P55 AC pre-amplifier, Grass Instrument Co., RI).
A midline incision was made in the neck of the animal to expose the right carotid artery, which was cannulated for invasive monitoring of arterial pressure via a pressure transducer (Ohmeda, Pty Ltd., Singapore). Once baseline monitoring parameters were recorded, a dose of 500 IU for antemortem heparin was delivered via a side port in the arterial pressure monitoring line. The animal was subjected to WLS via asphyxiation. A fixed warm ischemic time of 10 min followed by a 2-min stand-off period (to mimic Australian federal regulations regarding DCD heart retrieval (34) were purified from the cleavage reaction solutions using reversed-phase high-performance liquid chromatography. The mass of the purified peptides were confirmed using electrospray-ionisation mass spectrometry and pure peptides were lyophilised prior to confirmation of ASIC1a inhibitory activity using two electrode voltage clamp electrophysiology, as described previously for both Hi1a (26) and
PcTx1 (24, 67, 68) . Unless otherwise noted, lyophilized stocks of peptide were reconstituted in sterile deionised water prior to use.
Generation of cardiomyocytes from human induced pluripotent stem cells.
Cardiomyocytes generated in this study were derived from the WTC-11 hiPSC line (Gladstone Institute of Cardiovascular Disease, UCSF) (69, 70) . Undifferentiated hiPSCs were maintained on Vitronectin XF (5 µg/mL, Stem Cell Technologies) coated tissue culture dishes as per manufacturer recommendation with either mTeSR medium with supplementation or mTeSR PLUS medium with supplementation (Stem Cell Technologies). Contractile cardiomyocytes were differentiated using a high-density monolayer format as previously described (43) . On day 1 of differentiation, hiPSCs were dissociated with 0.5 mM EDTA solution supplemented with 1.1 mM D-glucose. Single-cell suspensions were plated at a density of 1.2 × 10 5 cells/cm 2 and cultured overnight in mTeSR medium supplemented with 10 µM Y-27632 dihydrochloride (Stem Cell Technologies). Once the monolayer reached approximately 80% confluence (usually the following day), differentiation was induced (day 0). The cells were quickly washed with phosphate-buffered saline (PBS) followed by a change in medium to RPMI (ThermoFisher) containing 3 µM CHIR99021 (Stem Cell Technologies), 500 µg/mL BSA (Sigma Aldrich), and 213 µg/mL ascorbic acid (Sigma Aldrich). After 3 days of culture, the medium was exchanged to RPMI containing 500 µg/mL BSA, 213 µg/mL ascorbic acid, and 5 µM Xav-939 (Stem Cell Technologies). On day 5, the medium was replaced with RPMI containing BSA and ascorbic acid as on day 3. Starting on day 7, the cells were fed every other day with RPMI containing B27 supplement with insulin (Life Technologies). Spontaneous beating was typically observed between days 9 and 11 of differentiation. 
In vitro ischemia-acidosis injury model with hiPSC-
Analysis of ASIC1 from GWAS studies of relevant conditions. To assess whether genetic variation
of ASIC1 associates with cardiovascular disease and stroke, we performed a gene-based level test on GWAS summary data using fastBAT (42) implemented in the Complex-Traits Genetics Virtual Lab (CTG-VL) (71) . GWAS summary data contains the statistical information of the association of all genetic variants included in a GWAS against a particular trait. fastBat tests the aggregated effects of a set of genetic variants within or close to (± 50 kb) each tested gene (ACCN1 in this case) using a setbased association approach that accounts for the correlation between genetic variants (i.e. linkage disequilibrium). This provides a more powerful approach over single-variant tests done in GWAS.
Specifically, we performed analyses using GWAS summary data for acute MI ( Table 1 .
Tables and Figures
Baseline functional parameters for Langendorff-perfused hearts from ASIC1a +/+ and ASIC1a -/mice Genotype Heart Rate All pre-ischemia functional parameters were measured after more than 30 min of stabilization, except for heart rate, which was measured after 15 min of stabilization, prior to ventricular pacing. All values are expressed as mean ± SEM. 
